PVX-108 for Peanut Allergy
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a treatment called PVX-108 to determine if it can safely reduce allergic reactions to peanuts in children and teens. Some participants will receive the treatment, while others will receive a placebo—a harmless substance resembling the treatment but with no effect—for comparison. The trial targets individuals diagnosed with a peanut allergy who have experienced allergic reactions to peanuts. Those whose peanut allergy affects daily life might find this trial suitable. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, if you have severe or unstable asthma, or are on certain asthma treatments, you may not be eligible to participate.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that PVX-108 is generally safe for people with peanut allergies. In earlier studies, adults with these allergies tolerated it well, with no serious side effects or allergic reactions linked to the treatment. Since PVX-108 doesn't contain whole peanut protein, it can be administered safely without the need to increase the dose over time. These findings suggest that the treatment is likely safe.12345
Why do researchers think this study treatment might be promising for peanut allergy?
Researchers are excited about PVX-108 for peanut allergy because it offers a novel approach to treatment. Unlike standard therapies that often involve oral immunotherapy, PVX-108 is administered through intradermal injections, which could potentially reduce the risk of severe allergic reactions. This treatment targets the immune system directly beneath the skin, aiming to desensitize the body to peanut allergens more safely and efficiently. By focusing on a different delivery method and mechanism of action, PVX-108 has the potential to provide a more tolerable and effective option for managing peanut allergies.
What evidence suggests that PVX-108 could be an effective treatment for peanut allergy?
Research has shown that PVX-108, which participants in this trial may receive, holds promise as a treatment for peanut allergies. Previous patients demonstrated that PVX-108 can safely reduce allergic reactions to peanuts. Specifically, one study found that PVX-108 treatment significantly reduced severe allergic reactions during peanut tests. This treatment calms certain immune cells, potentially lessening allergic responses. Overall, these findings suggest that PVX-108 could effectively manage peanut allergies, offering hope to those affected.12467
Who Is on the Research Team?
Brian Vickery, MD
Principal Investigator
Emory University
Are You a Good Fit for This Trial?
This trial is for children and adolescents with a doctor-confirmed peanut allergy, demonstrated by specific blood tests and skin prick tests. They must have had a reaction to a small amount of peanut protein in a controlled test. Kids with moderate or severe asthma are excluded, as well as those who've tried desensitizing treatments before.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive twelve 4-weekly intradermal doses of PVX108 or placebo
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- PVX-108
Find a Clinic Near You
Who Is Running the Clinical Trial?
Aravax Pty Ltd
Lead Sponsor